文献速递其他结缔组织病

抗CD40抗体iscalimab治疗原发性干燥综合征的随机对照概念验证研究

Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study.
PubMed 文献 · Lancet Rheumatol · 2020-01-23

这项多中心、随机、双盲、安慰剂对照的概念验证研究评估了抗CD40单克隆抗体iscalimab在原发性干燥综合征患者中的安全性和初步疗效。不良事件发生率与安慰剂组相似。

要点

  • 皮下iscalimab 3 mg/kg组ESSDAI评分与安慰剂无显著差异。
  • 不良事件发生率与安慰剂组相似,两例严重不良事件均与治疗无关。

核心结论

  • 静脉给予iscalimab 10 mg/kg可显著降低原发性干燥综合征患者的ESSDAI评分,提示CD40阻断在该病中具有治疗潜力。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照的概念验证研究,在欧洲和美国共10个中心开展,纳入符合2002年美国-欧洲共识组诊断标准的18-75岁原发性干燥综合征患者。
  • 患者按2:1随机分配至iscalimab组或安慰剂组,分为皮下3 mg/kg队列(队列1)和静脉10 mg/kg队列(队列2),均在0、2、4、8周给药,第12周起两组均开放标签接受iscalimab治疗12周。
  • 主要目标为评估两个序贯剂量队列的安全性和耐受性(通过不良事件)以及疗效(通过12周治疗后ESSDAI评分变化),分析基于符合方案集。

主要发现

  • 队列1中所有患者均发生不良事件;队列2中iscalimab组和安慰剂组不良事件发生率分别为52%和64%。
  • 报告了两例严重不良事件(队列1一例细菌性结膜炎,队列2一例心房颤动),均与iscalimab治疗无关。
  • 皮下iscalimab组与安慰剂组ESSDAI评分无显著差异。

关键数值与推荐

  • 皮下iscalimab 3 mg/kg组ESSDAI评分与安慰剂无显著差异。
  • 不良事件发生率:队列1全部患者发生;队列2 iscalimab组52%,安慰剂组64%。

临床怎么用

  • 静脉iscalimab 10 mg/kg在原发性干燥综合征中显示出初步疗效信号,支持进一步研究CD40阻断策略。
  • 皮下3 mg/kg剂量未显示优于安慰剂,剂量和给药途径可能影响疗效。
  • 安全性方面不良事件与安慰剂相似,严重不良事件与治疗无关。

局限性

  • 本研究为概念验证研究,样本量较小(队列1共12例,队列2共32例),疗效需更大规模研究确认。
  • 分析基于符合方案集,可能存在选择偏倚。
  • 开放标签延伸治疗阶段的结果未在本文报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary Sjögren's syndrome is an autoimmune disease that presents as dryness of the mouth and eyes due to impairment of the exocrine glands. To our knowledge, no systemic therapies for primary Sjögren's syndrome have shown efficacy. CD40-CD154-mediated T cell-B cell interactions in primary Sjögren's syndrome contribute to aberrant lymphocyte activation in inflamed tissue, leading to sialadenitis and other tissue injury. Therefore, we investigated the safety and preliminary efficacy of iscalimab (CFZ533), a novel anti-CD40 monoclonal antibody, in patients with primary Sjögren's syndrome. METHODS: This multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study took place at ten investigational sites across Europe (UK, n=4; Germany, Switzerland, and Hungary, n=1 each) and the USA (n=3). Eligible patients were aged 18-75 years and fulfilled the 2002 American European consensus group diagnostic classification criteria for primary Sjögren's syndrome. In the double-blind phase of the trial, patients were randomly assigned (2:1) via computer-generated unique randomisation numbers to receive subcutaneous iscalimab (3 mg/kg) or placebo at weeks 0, 2, 4, and 8 (cohort 1) or intravenous iscalimab (10 mg/kg) or placebo at weeks 0, 2, 4, and 8 (cohort 2). Randomisation was stratified according to baseline intake of oral corticosteroids. At week 12, patients in both cohorts received open-label iscalimab (same dose and route) for 12 weeks. The primary objectives of the study were to assess the safety, tolerability, and efficacy of multiple doses of iscalimab in the two sequential dose cohorts. Safety and tolerability were assessed by adverse events and efficacy of iscalimab versus placebo was assessed by clinical disease activity, as measured by the change in European League Against Rheumatism Sjögren's syndrome disease activity index (ESSDAI) score after 12 weeks of treatment. Analyses were done on a per-protocol basis. The trial was registered with ClinicalTrials.gov, NCT02291029. FINDINGS: Between Oct 22, 2014, and June 28, 2016, we assessed 82 patients for eligibility (25 for cohort 1 and 57 for cohort 2). 38 patients were excluded because of ineligibility. In cohort 1, 12 patients were randomly assigned to receive either 3 mg/kg doses of iscalimab (n=8) or placebo (n=4), and in cohort 2, 32 patients were randomly assigned to receive either intravenous 10 mg/kg doses of iscalimab (n=21) or placebo (n=11). Adverse events were similar between iscalimab treatment groups and placebo groups, with adverse events occurring in all patients in cohort 1, and in 52% and 64% of the iscalimab and placebo groups, respectively, in cohort 2. Two serious adverse events were reported (one case of bacterial conjunctivitis in cohort 1 and one case of atrial fibrillation in cohort 2), which were unrelated to treatment with iscalimab. Intravenous treatment with iscalimab resulted in a mean reduction of 5·21 points (95% CI 0·96-9·46; one-sided p=0·0090) in ESSDAI score compared with placebo. There was no signficiant difference in ESSDAI score between subcutaneous iscalimab and placebo. INTERPRETATION: To our knowledge, this is the first randomised, placebo-controlled proof-of-concept study of a new investigational drug for primary Sjögren's syndrome that indicates preliminary efficacy. Our data suggest a role of CD40-CD154 interactions in primary Sjögren's syndrome pathology and the therapeutic potential for CD40 blockade in this disease should be investigated further. FUNDING: Novartis Pharma.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Fisher BA, Szanto A, Ng WF, et al. Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study. Lancet Rheumatol. 2020. PMID: 38263652. doi:10.1016/S2665-9913(19)30135-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。